CXCL16 and breast carcinoma: For example, anti-CXCL16 blockade in mouse breast cancer liberates CXCR6+ effectors from primary tumors, driving their migration and differentiation into lung TRM cells (see Section 3) and highlighting a promising target for TRM-directed therapies [15].